Commitment (Details Textual) (USD $)	1 Months Ended				12 Months Ended					129 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended		12 Months Ended			1 Months Ended		12 Months Ended													12 Months Ended		12 Months Ended
	Jan. 31, 2007	May 31, 2006	Feb. 28, 2006	Feb. 28, 2005	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2007	Dec. 31, 2004	Dec. 31, 2012	Dec. 31, 2012 Phase III Clinical Trial [Member]	Dec. 31, 2012 Phase III Clinical Trial [Member]	Dec. 31, 2012 Phase II Clinical Trial [Member]	Jun. 30, 2012 Other Contractual Obligations [Member]	Dec. 31, 2012 Contract Research and Manufacturing Purchase Obligations [Member]	Dec. 31, 2011 Contract Research and Manufacturing Purchase Obligations [Member]	Dec. 31, 2010 Contract Research and Manufacturing Purchase Obligations [Member]	Dec. 31, 2006 Use Rights [Member] Development and Commercialization Agreement With Active Biotech [Member]	May 31, 2006 Use Rights [Member] Development and Commercialization Agreement With Active Biotech [Member]	Dec. 31, 2006 Use Rights [Member] Development and Commercialization Agreement With Active Biotech [Member]	Dec. 31, 2010 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2009 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2008 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2007 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2006 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2005 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2004 License Agreement With Gopal Nair [Member] Use Rights [Member]	Dec. 31, 2012 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Dec. 31, 2011 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Dec. 31, 2008 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Dec. 31, 2006 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member]	Dec. 31, 2012 License Agreement With Dainippon Sumitomo Pharma [Member] Use Rights [Member] N D A [Member]	Dec. 31, 2006 Finders Agreement [Member] Warrant [Member]	Dec. 31, 2012 Finders Agreement [Member] Warrant [Member]	Dec. 31, 2012 Facility Lease [Member]	Dec. 31, 2011 Facility Lease [Member]	Dec. 31, 2010 Facility Lease [Member]	Dec. 31, 2011 License Agreement [Member]	Dec. 31, 2010 License Agreement [Member]
Operating Leases, Rent Expense																																			$ 358,439	$ 339,963	$ 202,267
Lease Expiration Date																																			Mar. 11, 2016
Operating Leases, Future Minimum Payments Due																																			1,200,000
Operating Leases, Frequency Of Periodic Payment																																			monthly
Operating Leases, Periodic Payment																																			30,000
Percentage Of Increases In Annual Rent																																			3.00%
Security Deposit																																			38,000
Initial Payment Towards Use Of Rights As Per License Agreement																											150,000				100,000
Value Of Common Stock Issued During Period Towards Milestone Payment																								150,000	100,000	100,000
Common Stock Shares Issued During Period To wards Milestone Payment																							30,612	26,643
Fair Value Of Common Stock Issued During Period Towards Milestone Payment																							$ 4.90	$ 5.63
Milestone Payment Made During Period																					100,000	150,000	100,000						750,000	500,000
Potential Future Milestone Payments																					1,500,000							2,500,000				1,500,000		150,000
Common Stock Shares Issued During Period Towards Right To Use Intellectual Property																															63,131
Fair Value Of Common Stock Issued During Period Towards Right To Use Intellectual Property																															$ 4.35
Value Of Common Stock Issued During Period Towards Right To Use Intellectual Property																															274,621
Research and Development Expense (Excluding Acquired in Process Cost)															1,200,000	3,800,000	1,900,000											3,100,000										750,000	100,000
Warrants issued to purchase common stock	0	250,000	716,666	105,516					483,701
Common stock warrants, purchase price		$ 4.31	$ 3.3	$ 2.62					$ 2.88
Fair Value Of Warrants Granted	433,750		705,000	26,700					14,400
Weighted-average risk-free interest rate					0.74%	1.83%	2.39%																										4.79%
Weighted-average expected life of options					5 years	5 years	5 years																										3 years
Expected dividend yield					0.00%	0.00%	0.00%																										0.00%
Weighted-average expected volatility					89.73%	87.82%	93.95%																										66.01%
Research and development					16,744,423	37,270,138	30,871,125	600,000		162,504,846		1,600,000				7,200,000		1,000,000	1,000,000
Additional Research And Development Expense																				300,000
Purchase Commitment, Remaining Minimum Amount Committed															1,500,000
Decrease In Research and Development Expense											900,000		500,000
Increase In Research and Development Expense											500,000
Sales and marketing					$ 7,221,800	$ 8,067,709	$ 2,476,494			$ 24,246,376				$ 100,000